HOME ·

CSPC PHARMA

CSPC PHARMA (01093.HK): Batoclimab injection wins China approval
Tags：
CSPC PHARMA01093.HKDrug Approval
2026-10-23
CSPC PHARMA (01093.HK): Phase III Trial of SYS6043 in First-Line Triple-Negative Breast Cancer Launched in China
Tags：
NewTimeSpaceCSPC PHARMA01093.HK
2026-10-22
CSPC PHARMA (01093.HK): Phase II Trial in China of SYH2066 for RSV Launched
Tags：
CSPC PHARMA01093.HKRSV
2026-10-22
CSPC PHARMA (01093.HK): Phase I Trial of SYH2083 Eye Drops for Dry Eye Disease Launched in China
Tags：
NewTimeSpaceCSPC PHARMA01093.HK
2026-10-20
CSPC PHARMA (01093.HK): Grants 78.085m award shares to 205 people
Tags：
CSPC PHARMA01093.HKShare Award Scheme
2026-10-16
CSPC PHARMA (01093.HK): SYS6062 ADC gets China clinical trial nod
Tags：
CSPC PHARMA01093.HKDrug Development
2026-10-15
CSPC PHARMA (01093.HK): SYS6088 trispecific antibody gets CT nod
Tags：
CSPC PHARMA01093.HKDrug Development
2026-10-15
CSPC PHARMA (01093.HK): Phase I Data for SYS6002 in Advanced Cervical Cancer; Confirmed ORR Up to 35.9%
Tags：
NewTimeSpaceCSPC PHARMA01093.HK
2026-10-08
CSPC PHARMA (01093.HK): 8 trials to feature at ESMO 2026, two as LBAs
Tags：
CSPC PHARMA01093.HKClinical Trial
2026-10-05
CSPC PHARMA (01093.HK): Efmedaglutide Alfa Phase III Data at EASD 2026
Tags：
CSPC PHARMA01093.HKInnovative Drugs
2026-09-30
CSPC PHARMA (01093.HK): JMT206 Phase Ib Obesity Trial Starts in China
Tags：
CSPC PHARMA01093.HKInnovative Drugs
2026-09-29
CSPC PHARMA (01093.HK): SYS6077 injection wins clinical trial nod
Tags：
CSPC PHARMA01093.HKR&D Progress
2026-09-28
CSPC PHARMA (01093.HK): Phase III Trial of Becotatug (JMT101) plus Osimertinib Meets Primary Endpoint, Significantly Extending PFS
Tags：
NewTimeSpaceCSPC PHARMA01093.HK
2026-09-24
CSPC PHARMA (01093.HK): HB1801 Phase III Trial Starts in China
Tags：
CSPC PHARMA01093.HKPhase III Trial
2026-09-24
CSPC PHARMA (01093.HK): Phase II Trial of SYH2069 Injection for Adult Type 2 Diabetes Commences at First Site in China
Tags：
CSPC PHARMA01093.HKR&D Progress
2026-09-16
CSPC PHARMA (01093.HK): SYS6010 Included in China's Breakthrough Therapy Designation List for Driver-Gene-Negative Non-Squamous NSCLC
Tags：
CSPC PHARMA01093.HKR&D Progress
2026-09-15
CSPC PHARMA (01093.HK): Phase I/II Data of SYS6010 Combined with Enlangsuba Monoclonal Antibody in Previously Untreated Driver-Gene-Negative Advanced NSCLC Presented as Oral Presentation at 2026 WCLC
Tags：
CSPC PHARMA01093.HKR&D Progress
2026-09-14
CSPC PHARMA (01093.HK): SYH9087, China's First Subcutaneous Rotigotine Long-acting Product, Cleared for Clinical Trials
Tags：
CSPC PHARMA01093.HKR&D Progress
2026-09-09
CSPC PHARMA (01093.HK): SYH9102, World's First Ready-to-use Goserelin Extended-release Injection, Cleared for Clinical Trials in China
Tags：
CSPC PHARMA01093.HKClinical Trial
2026-09-09
CSPC PHARMA (01093.HK): Innovative Chemical Drug SYH2083 Eye Drops Obtains Clinical Trial Approval in China for Dry Eye Disease
Tags：
CSPC PHARMA01093.HKClinical Trial
2026-09-08
123